PPARGC1A and cerebral infarction: Medioresinol, a PGC-1α activator, reduces cerebral infarct volume and blood‒brain barrier permeability through the PPARα/GOT1 axis, inhibits endothelial cell pyroptosis, and promotes long-term neurobehavioral recovery [39].